Related Experiment Video
Updated: Apr 27, 2026

11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.9K
The squares test as a measure of hand function in multiple sclerosis
Jeroen Gielen1, Jorne Laton1, J Van Schependom2
1Center for Neurosciences, C4N, Faculty of Medicine and Pharmaceutical Sciences UZ Brussel, Laarbeeklaan, 101, Brussels 1090, Belgium.
Clinical Neurology and Neurosurgery
|July 12, 2014
Summary
The Squares Test (ST) reliably assesses hand function in multiple sclerosis (MS) patients. This paper-based test correlates highly with the 9-hole peg test (9HPT), offering a valid alternative for clinical use.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Clinical Assessment
Background:
- Hand function impairment is a significant challenge in multiple sclerosis (MS).
- The 9-hole peg test (9HPT) is the standard assessment for hand function in MS.
- There is a need for validated, easily administered hand function tests in MS research and clinical practice.
Purpose of the Study:
- To evaluate the reproducibility, discriminatory power, and concurrent validity of the Squares Test (ST) for assessing hand function in individuals with MS.
- To compare the ST's performance against the established 9HPT.
Main Methods:
- The ST's reproducibility was assessed in 49 healthy controls.
- Discriminatory power and concurrent validity were evaluated in 38 MS patients and 18 age/gender-matched controls.
- Correlation analysis was performed between the ST and the 9HPT across a range of Expanded Disability Status Scale (EDSS) scores.
Main Results:
- The ST demonstrated excellent reproducibility in healthy controls.
- The ST showed a high and statistically significant correlation with the 9HPT in MS patients.
- The ST exhibited high discriminatory power, comparable to the 9HPT, across various EDSS levels.
Conclusions:
- The Squares Test is a reliable, valid, and easily administered paper-and-pencil assessment for hand function in MS.
- The ST is a potential candidate for inclusion in composite measures of MS-related functional deficits for clinical trials and practice.

